JCI The Journal of Clinical Investigation

CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA

Honghe Liu, ..., Lindsey R. Hayes, Jiou Wang

J Clin Invest. 2024;134(24):e189439. https://doi.org/10.1172/JCI189439.

Corrigendum

Original citation J Clin Invest. 2024;134(21):e179016. https://doi.org/10.1172/JCI179016 Citation for this corrigendum: J Clin Invest. 2024;134(24):e189439. https://doi.org/10.1172/JCI189439 During the preparation of this manuscript, an involved patent was mistakenly omitted from the conflict-of-interest statement. The correct statement is below. The HTML and PDF versions of the manuscript have been updated. HL and JW are listed as inventors on a patent application (application number: 63313150) filed by Johns Hopkins University on technologies related to this manuscript.



Find the latest version:

https://jci.me/189439/pdf

Corrigendum

CRISPR/Cas13d targeting suppresses repeat-associated non-AUG translation of C9orf72 hexanucleotide repeat RNA

Honghe Liu, Xiao-Feng Zhao, Yu-Ning Lu, Lindsey R. Hayes, and Jiou Wang

Original citation J Clin Invest. 2024;134(21):e179016. https://doi.org/10.1172/JCI179016

Citation for this corrigendum: J Clin Invest. 2024;134(24):e189439. https://doi.org/10.1172/JCI189439

During the preparation of this manuscript, an involved patent was mistakenly omitted from the conflict-of-interest statement. The correct statement is below. The HTML and PDF versions of the manuscript have been updated.

HL and JW are listed as inventors on a patent application (application number: 63313150) filed by Johns Hopkins University on technologies related to this manuscript.